Lakefront Biotherapeutics (GLPGF) Net Income towards Common Stockholders (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Net Income towards Common Stockholders for 13 consecutive years, with -$50.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 128.49% year-over-year to -$50.2 million in Q2 2026; TTM through Jun 2026 was $373.4 billion, a 372.59% increase from a year earlier, with the FY2025 full-year figure at $362.5 billion, up 352.15% from the prior year.
• Net Income towards Common Stockholders was -$50.2 million for Q2 2026 at Lakefront Biotherapeutics, down from $17.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $374.1 billion in Q4 2025 and troughed at -$582.7 million in Q3 2025.
• A 5-year average of $37.8 billion and a median of $19.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 97461.3% in 2023 and slumped 447.41% in 2025, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at $233.4 million in 2022, then jumped by 97461.3% to $227.7 billion in 2023, then sank by 65.26% to $79.1 billion in 2024, then soared by 372.83% to $374.1 billion in 2025, then plunged by 100.01% to -$50.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$50.2 million (Q2 2026), $17.0 million (Q1 2026), and $374.1 billion (Q4 2025), per Business Quant data.